323
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy

, , , , , , & show all
Pages 3532-3533 | Received 20 Jul 2020, Accepted 04 Aug 2020, Published online: 19 Aug 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Tamer A. Othman, Matthew E. Tenold, Benjamin N. Moskoff, Tali Azenkot & Brian A. Jonas. (2021) An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia. Expert Review of Hematology 14:5, pages 407-417.
Read now

Articles from other publishers (3)

Onyee Chan & Alison R. Walker. (2023) Novel therapies upon failure of HMA plus venetoclax. Hematology 2023:1, pages 702-708.
Crossref
Nina Rosa Neuendorff, Nico Gagelmann, Surbhi Singhal, Shelby Meckstroth, Vincent Thibaud, Yue Zhao, Nabiel Mir, Yung-Yu Shih, Danielle M.C. Amaro, Mukul Roy, Joseph Lombardo, Lars Klingen Gjærde & Kah Poh Loh. (2023) Hypomethylating agent-based therapies in older adults with acute myeloid leukemia – A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee. Journal of Geriatric Oncology 14:3, pages 101406.
Crossref
Omur Gokmen Sevindik, Mahmut Mergen, Sena Mergen, Yasa Gul Mutlu, Berrin Balık Aydın & Istemi Serin. (2022) To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission. Annals of Hematology 101:11, pages 2545-2547.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.